MiNK Therapeutics reports FY2023 net loss $22.5M; cash $3.4M at year-end

MiNK Therapeutics, Inc.

Net loss for 2023 was $22.5M ($0.65/share) vs. $28.0M ($0.83/share) in 2022.
Cash and cash equivalents $3.4M at Dec 31, 2023; received $5M post-year-end from Agenus convertible note.
Launched Phase 2 trial of agenT-797 with botensilimab/balstilimab/chemo in 2L gastroesophageal cancers.
Entered collaboration with Immunoscape to develop TCR-based therapies against novel targets.
Nature Communications publication showed >70% survival in ARDS patients on mechanical ventilation with agenT-797.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MiNK Therapeutics, Inc. reported fourth quarter and full-year 2023 results: net income Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, EPS $0.65.

Period: fourth quarter and full-year 2023
Net income: Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share
EPS: $0.65
Result: reported results

Exact text from the filing

MiNK Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

MiNK Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001514

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.